The major clinical manifestation of Coronavirus disease 2019 (COVID-19) infection is an interstitial pneumonia with different phenotypes, the most severe consisting in acute respiratory distress syndrome, typically followed by disseminated intravascular coagulation (DIC) and fatal multi organ failure (MOF) ([@bib0001]). SARS-CoV-2 is thought able to invade CNS through the olfactory bulbs epithelium, which shows a higher expression of the protein hACE2, the receptor identified as the one used to gain entry into the host ([@bib0001]), or carried into the brain by the blood, with subsequent infection of vascular endothelium or macrophages. Many factors have drawn the attention of neurologists: a significant number of cases of altered mental status and other neurological symptoms like anosmia and ageusia ([@bib0002]). The first report of acute necrotizing encephalopathy (ANE), a rare complication of influenza and other viral infections, in a COVID positive female patient, has increased even more the alert in the neurological community ([@bib0003]). This issue sounds relevant in particular for patients treated with immunosuppressant drugs. In Multiple Sclerosis (MS), prolonged treatment with natalizumab can reduce immune surveillance in the CNS, increasing the risk that poliomavirus JC could establish a lytic infection in oligodendrocytes, leading to Progressive Multifocal Leukoencephalopathy (PML). To limit the onset of this peculiar adverse event we adopted strategies to mitigate the risk, such as dosing of natalizumab in a less frequent range (extended interval dosing-EID) of 6-8 weeks, differently from the approved treatment schedule of every 4 weeks (standard interval dosing-SID) ([@bib0004]).

We report a case of COVID-19 in a patient with MS treated with the monoclonal antibody natalizumab (humanized anti-VLA4), a 28-year old Caucasian health worker male (118 emergency ambulance driver). He received the diagnosis in the year 2000, when he developed acute upper and lower limb hyposthenia on the left side. Nothing relevant appears in his past medical history. He was previously treated with dimethyl fumarate and has always tested JCV-negative. At the end of February 2020, he underwent his 14th infusion in an EID regimen at 6 weeks. Routine haematological screening resulted in normal peripheral blood lymphocyte count; renal and hepatic function parameters were in the normal range. Expanded disability status scale (EDSS) was 1.5. On March 11 he developed a fever (38,6°C), no other symptoms. PCR on nasal swab resulted positive for SARS-CoV-2 on two consecutive samples. He was admitted to Spallanzani Hospital in Rome on March 19, due to persistent high fever and the emergence of dyspnoea. Chest CT showed mild bilateral interstitial pneumonia with ground glass opacities and arterial blood gas test showed normal blood oxygenation. Patient was treated with antipyretics, hydroxychloroquine and antibiotics, with resolution of symptoms within 10 days. He was discharged home on the 1^st^ of April after double-negative swabs. Patient returned to our hospital for treatment infusion at 7 weeks, still in the window of the EID. Blood exams showed normal leucocyte and lymphocyte count (5.68 × 10\^9 cells/L, range 4.00-10.00 and 2.17 × 10\^9 cells/L, range 1.00-4.50, respectively), with normal C-reactive protein (0,4 mg/L, range 0-5) and a slight increase of fibrinogen (467 mg/dl, range 150-450). At 2 weeks from the last administration, the patient is still at home due to the institutional lockdown, without the onset of any new symptoms or worsening of previous clinical conditions. Most notably, he hasn\'t developed any respiratory symptoms. To our knowledge, this is the first reported case of a natalizumab treated patient developing COVID-19, recovered and then retreated, without short-term complications.

Although natalizumab potentially blocks viral immunosurveillance of the CNS, PML is a rare event: approximately a total of 765,985 patient-years has been exposed globally in the post approval setting, with overall PML incidence of 4.08 per 1,000 (95% CI, 3.80-4.36 per 1,000 patients). EID has been suggested to reduce significantly PML risk compared to SID ([@bib0004]). At the time being, it is unknown if natalizumab could potentially be a risk factor for a severe PML-mimicking Neuro-COVID encephalopathy, whereas the risk of recurrence of disease activity when discontinuing natalizumab is deeply documented ([@bib0005]). Arising data on SARS-CoV-2 neurotropism and about how the virus may be carried into the CNS will mitigate or clarify present concerns.
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